Dr Edward B Garon, Dr Tiffany A Traina, and nurse practitioners Ms Marianne J Davies and Ms Marissa Marti-Smith discuss the role of antibody-drug conjugates in the care of patients with breast and lung cancer and strategies to mitigate and manage treatment-emergent adverse events.

NCPD information and select publications here.

Dr Justin F Gainor from Massachusetts General Hospital in Boston reviews available clinical data on ALK inhibitors and first-line treatment strategies for ALK-positive metastatic non-small cell lung cancer.

CME information and select publications here.

Dr Enriqueta Felip from the Vall d’Hebron Institute of Oncology in Barcelona, Spain, and Dr Helena Yu from Memorial Sloan Kettering Cancer Center in New York, New York, discuss current and emerging treatment approaches for patients with EGFR-mutant non-small cell lung cancer.

CME information and select publications here

Dr Edward B Garon shares his perspectives on the evolving therapeutic landscape for patients with lung cancer.

Dr Heather Wakelee from Stanford University School of Medicine in California discusses the implications of recent datasets for the current and future use of nontargeted therapy for metastatic non-small cell lung cancer.

Dr Suresh S Ramalingam from the Emory University School of Medicine in Atlanta, Georgia and Dr Gregory J Riely from Memorial Sloan Kettering Cancer Center in New York, New York discuss the implications of recent data sets for the current and future management of lung cancer.

Specialist clinical investigators share their perspectives on the evolving therapeutic landscape for patients with lung cancer.

Dr Stephen V Liu from Georgetown University Hospital in Washington, DC, reviews recently presented data with and newly approved therapies for localized and advanced lung cancers.